CD274 and non-small cell lung carcinoma: Also, clinical data from a large cohort of patients with non-small cell lung cancer, renal cell carcinoma, or urothelial cancer suggested that patients treated with antibiotics for routine indications shortly before, during, or shortly after treatment with anti-PD1/PD-L1 mAB had significantly lower PFS and OS rates compared to patients who had not received antibiotics, suggesting that disrupted the gut microbiota via antibiotic use could potentially impair anti-tumor immune responses and resulted in acquired resistance to ICIs [89].